Literature DB >> 161170

Combined cholinergic antagonist and beta 2-adrenoceptor agonist bronchodilator therapy by inhalation.

G E Marlin, N Berend, A C Harrison.   

Abstract

The bronchodilator effects of 40 microgram ipratropium bromide (I) and 400 microgram fenoterol (F) by pressurised aerosol and both drugs in combination were compared with placebo (P) in a double-blind study in eight patients with chronic, partially reversible airways obstruction. The four treatments were (1) IP, (2) PF, (3) IF and (4) PP, with the second aerosol administered two hours after the first. Both drugs produced significant bronchodilatation for five hours, the response being greater and more rapid in onset with fenoterol. Both drugs in combination (IF) produced significant additive bronchodilatation from three to six hours after fenoterol. This additive effect may have been due to the improved lung function caused by ipratropium bromide and does not imply a synergistic effect. There were no side-effects reported. The results suggest that both ipratropium bromide and fenoterol are effective bronchodilating agents in patients with chronic asthma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 161170     DOI: 10.1111/j.1445-5994.1979.tb03386.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  8 in total

1.  A comparison between a combination of ipratropium bromide plus fenoterol in a single metered dose inhaler (Duovent) and salbutamol in asthma.

Authors:  K C Flint; B Hockley; N M Johnson
Journal:  Postgrad Med J       Date:  1983-11       Impact factor: 2.401

2.  Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema.

Authors:  J A Hughes; M J Tobin; D Bellamy; D C Hutchison
Journal:  Thorax       Date:  1982-09       Impact factor: 9.139

Review 3.  Combination bronchodilator therapy.

Authors:  G M Shenfield
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

4.  Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation.

Authors:  I G Brown; C S Chan; C A Kelly; A G Dent; P V Zimmerman
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

Review 5.  Anticholinergic agents for chronic asthma in adults.

Authors:  M Westby; M Benson; P Gibson
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 6.  Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

7.  Bronchodilator responses to nebulised ipratropium and salbutamol singly and in combination in chronic bronchitis.

Authors:  C S Chan; I G Brown; C A Kelly; A G Dent; P V Zimmerman
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

8.  Ipratropium bromide and fenoterol by aerosolized solution.

Authors:  C R Jenkins; C M Chow; B L Fisher; G E Marlin
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.